Aprea Therapeutics, Inc. Initial Public Offering

Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000 shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. Aprea Therapeutics, Inc. is listed on the Nasdaq Global Select Market under the symbol “APRE.”

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Derek Dostal, and associate Jennifer Ying Lan. Partner Pritesh P. Shah, counsel Bonnie Chen and associate Hilary Smith provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Joseph M. Gerstel. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices.